




**Europass
Curriculum
Vitae**



**Personal
information**

First name(s) / **Luca Morandi**
Surname(s)

Address(es) Via Protti 6, 40139 BOLOGNA Italy

Telephone(s) +390516225015

Mobile: +39 3288060973

Fax(es) +39 051 6225759

E-mail luca.morandi2@unibo.it

Nationality Italian

Date of birth 28/09/1967

Gender Male

Occupational field **Actual position: Associate Professor, Department of Biomedical and Neuromotor Sciences, University of Bologna**

Work experience

March 2021: engaged at the Azienda USL of Bologna at the IRCCS Istituto delle Scienze Neurologiche di Bologna, Functional and Molecular Neuroimaging Unit, Bellaria Hospital, via Altura 3, 40139 Bologna, Italy

October 2019: engaged as a senior assistant professor (fixed-term) at the Department of Biomedical and Neuromotor Sciences, University of Bologna (Scientific area: Clinical Biochemistry and molecular biology)

Since Dec 2005 he was engaged at the Dept of Biomedical and Neuromotor Sciences - DIBINEM – University of Bologna, section of Anatomic Pathology Bellaria Hospital (actual position D2, Senior Research Technician)

Dec 2013- Feb 2017: Founder and R&D consultant of 4Bases SA, CH(www.4bases.ch)

Sept 2003-2012: Founder and consultant of Alphagenics Biotechnologies S.r.l. Area Science Park Basovizza, Trieste (www.alphagenicsbiotech.com)

July 1996-Aug 2003: R&D Scientific Director and founder of Alphagenics Biotechnologies S.r.l. Area Science Park Padriciano 99 Trieste

2009-2010: Principal Investigator of the project entitled “Metodo predittivo di prognosi e risposta alla chemioterapia nel cancro alla mammella” supported by grant Friuli Venezia Giulia, proposal 2009

2007-2008: Principal Investigator of the project entitled “Genomics and Epigenomics of primary breast cancer and recurrence” supported by grant Friuli Venezia Giulia, proposal 2007

2007-2008: Principal Investigator of the project entitled “AlphaReal Beacon” supported by grant Friuli Venezia Giulia, proposal 2007

1999-2000: Principal Investigator of the project entitled “DNA Chips e High Density Microarray per lo Studio di Tumori Umani” supported by grant Fondo Trieste, proposal 1999

1999: Principal Investigator of the project entitled “Metodi innovativi di individuazione di nuovi marker tumorali e poliforfismi genetici correlati a particolari patologie” supported by grant Regione Friuli Venezia Giulia proposal 1999

1996-1998: Principal Investigator of the project entitled “Alphagenics” supported by EU grant Objective 2 94/96

May 1995-June 1996: Product Specialist NLM - Innogenetics

Education and training

Dates 1993: Academic Degree in Biology, at the faculty of Mathematics, Physics and Natural Sciences of Bologna (Thesis Title: Gene expression analysis of malic enzyme in *Zea mays*)
 1999 Specialty in Applied Genetics at the faculty of Mathematics, Physics and Natural Sciences of Bologna (Thesis Title: Ancient DNA: purification and analysis in human skeletal remains")
 2003 *PhD* in Oncology, at the University of Bologna – Department of Experimental Pathology (Thesis Title: Intraepidermal Cells of Paget’s Carcinoma of the Breast Can Be Genetically Different From Those of the Underlying Carcinoma)
 2003-2004 Post Doc fellowship at Department of Experimental Pathology, University of Bologna
 Tutorship of the following *PhD* thesis:
 - Dr Gissi Davide XXVII cycle: Profili di espressione genetica ed epigenetica ad impatto prognostico e predittivo nel carcinoma squamoso e nelle lesioni potenzialmente maligne del cavo orale; - Dr Visani Michela XXV cycle: MicroRNAs expression analysis in high grade gliomas; - Dr. Baldissera Antonella XXI cycle: Focalita’ e clonalita’ nei carcinomi in situ ed invasivo mammari, studio genetico e nuove tecniche di radioterapia; - Dr del Corso Giacomo XXIX cycle: MicroRNA in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Lesions: from biological discovery to clinical utility; - ongoing: Dr Andrea Gabusi XXX cycle: tumor heterogeneity in oral squamous cell carcinoma

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) **English: CLA UNIBO certified**

Self-assessment
 European level (*)

English

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
C1	C1	C1	C1	C1

(*) [Common European Framework of Reference for Languages](http://www.cerl.eu)

Courses “Biotechnology for development”, ICGEB, Trieste, 1999
 “Practical course: Bioinformatics: Computer methods in molecular biology”, ICGEB, 9/07/1999-16/07/1999, Trieste
 “7th Cancer Genetics” 26-29/08/02, Bertinoro 2002
 “8th Course in Cancer Genetics” 5-9/09/2003, Bertinoro 2003
 “5th Course in Molecular Cytogenetics and DNA Arrays”, Bertinoro 2003
 “6th Course in Molecular Cytogenetics and DNA Arrays”, Bertinoro 2004
 “7th Course in Molecular Cytogenetics and DNA Arrays”, Bertinoro 2005
 “9th Course in Cancer Genetics”, Bertinoro 2005
 “8th Course in Molecular Cytogenetics and DNA Arrays”, Bertinoro 2006
 “Bioinformatics for the management, analysis and interpretation of microarray data” CINECA, Bologna 2003
 “2nd Course in Integration of cytogenetics, microarrays and massive sequencing in biomedical and clinical research
 Course in data analysis of 454 Deep Sequencing using LINUX/PERL; Roche Diagnostics, Monza, 19/07/2011

Technical experiences
and computer skills

Skills: DNA Sequencing; Fragment Analysis; LOH analysis and microsatellite instability; Gene expression microarrays(Agilent platform); CGH-arrays (Agilent Platform); Real time PCR; Laser assisted microdissection, Reverse Dot/Blot (ASO), PCR-ELISA, quantitative competitive PCR, PCR-RFLP, PCR-DGGE, Western Blotting, Northern Blotting, Southern Blotting, methylation sensitive PCR; quantitative methylation sensitive Real Time PCR by Molecular beacon;

Next Generation Sequencing: MiSEQ-Illumina at IRCSS Neuroscience Bellaria Hospital, MiniSEQ at 4Bases SA; IonTorrent at ARC-NET University of Verona; 454-GSJunior Roche at Anatomia Patologica Bellaria Hospital) for mutation analysis, DNA methylation (Bisulfite-SEQ), Copy number variation, splicing variant discovery, microRNA expression, NGS bioinformatic data analysis by perl; bismarck bisulfite read mapper, Galaxy cloud computing (<http://usegalaxy.org/>), BaseSpace including BWA, VariantStudio, NextGene, SeqPilot, CLC Genomic Workbench, BISMA (<http://services.abc.uni-stuttgart.de/BDPC/BISMA/>), BSPAT (<http://cbc.case.edu/BSPAT/>), .

Patents

- WO2014009798 (a1) gene expression profiling using 5 genes to predict prognosis in breast cancer; Inventor: Luca Morandi MP Sormani, JL Centeleghe
- EP 2218794 (A1) - Detection of instability in regions of genomic DNA containing simple tandem repeats demande 00233/09 (Art. 46b al. 1 OBI)
Applicant: Alphagenics International SA Inventor: Luca Morandi Title: Detection of instability in regions of genomic DNA containing simple tandem repeats
- EP 2218793 (A1) - Detection of MGMT methylation in tumors P1994CH00 / 201-9 Demande 00232/09 Applicant : Alphagenics International Sarl ; Inventor : Luca Morandi; Title : Promoter methylation analysis of O6-methylguanine-DNA methyltransferase (MGMT) detected by locked nucleic acid based quantitative PCR and molecular beacon chemistry using an imprinted gene (SNURF) as a reference
- WO2011104694 (A2) Inventor: Luca Morandi, " Detection of BRAF V600E mutation by allele specific real time quantitative PCR (AS-qPCR) using locked nucleic acids primers and beacon probes" Au nom de : Gammagenetics Sarl V/Réf. : BRAF N/Réf. : P2121PC00 / 0649-004
- WO2011104695 (A2) Inventor: Luca Morandi, "Detection of kras mutation in exon 2 by allele specific real time quantitative PCR (AS-QPCR)" Au nom de : Gammagenetics Sarl V/Réf. : KRAS N/Réf. : P2122PC00 / 0649-005
- PCT/IB2017/056875, EP3374527: Inventors: Luca Morandi, Davide Gissi, Achille Tarsitano: Quantitative DNA Methylation analysis to early detect Oral Squamous Cell Carcinoma from exfoliating brushes of oral mucosa Applicant: University of Bologna

Awards

- Award: "Gene expression profiling in gliomas and IHC evaluation of IGFBP-2" presented at the 3rd Intercontinental Congress of Pathology Barcelona 2008
- Award: Innovation 3L 3T "Early Birds" 2008 AREA Science Park (Trieste) kit ALphaReal KRAS
- Award: Innovation 3L 3T "Early Birds" 2009 AREA Science Park (Trieste) kit ALphaReal BRAF
- Award: Innovation 3L 3T "Early Birds" 2012 AREA Science Park (Trieste) kit ALphaReal MGMT
- Award: Best Poster XIV congresso nazionale Società Italiana di Patologia e Medicina Orale (SIPMO 2017)

Educational Activity:

Luca Morandi is professor of the following courses at the University of Bologna:

39305 - Applied Clinical Biochemistry - 2 cfu Module of Clinical Biochemistry II (I.C.)

83169 - Clinical Biochemistry - 1 cfu Module of Diagnostic Technology (I.C.)

08956 - Clinical Biochemistry (A-K) - 1 cfu Module of Laboratory Medicine (Integrated Course)

08956 - Clinical Biochemistry (L-Z) - 1 cfu Module of Laboratory Medicine (Integrated Course)

20729 - Clinical Biochemistry and Clinical Molecular Biology - 2 cfu Module of Laboratory Medicine - (C.I.)

84437 - In Vivo Neurometabolic Diagnostics (Module 2) Module of Neurometabolic and Neurodegenerative Disorders (I.C.)

Medical Biotechnology: 82287 - Internship - 4 cfu

Research activity:

Publications (from Scopus): **H-index: 27 (Scopus 10/10/2022), 105 documents, citations: 2000.**

ORCID ID: orcid.org/0000-0002-3810-9760

Scopus ID: 7005265175

Researcher ID: A-3191-2016

Publons: publons.com/a/1359859/

Ad hoc Reviewer of the following impacted Journals: International Journal of Molecular Sciences; CCLM; Sensors; Journal of Virological Methods; Human Pathology; Virchow Archives; Archives of Oral Pathology; BBA - Molecular Basis of Disease; Medical Science Monitor; Advances in Cancer Prevention; Cancers; Cancer Biomarkers; Cancer Medicine; Journal of International Medical Research; Expert Review of Molecular Diagnostics; Epigenetics; BMC Cancer; Biomedicine; Cancer Biology and Medicine; Epigenomics; Future Oncology; Journal of Clinical Medicine; Oral Diseases; Member of SIAPEC-IAP, European Society of Pathology (ESP), SIBIOC.

Publications:

- Russo F, Notarnicola M, Di Matteo G, Leoci C, Caruso ML, Pirrelli M, Caradonna M, **Morandi L**, Di Leo A; Detection of Helicobacter pylori cagA gene by polymerase chain reaction in faecal samples. Eur J Gastroenterol Hepatol 1999 Mar;11(3):251-6
- Foschini MP, **Morandi L**, Macchia S, Dal Monte PR, Pession A. Dimostrazione del virus TT in tessuto epatico fissato in formalina ed incluso in paraffina; Pathologica 2001 Apr;93(2):112-7
- Comar M, Ansaldi F, **Morandi L**, Dal Molin G, Foschini PM, Croce SL, Bonin S, Stanta G, Tiribelli C, Campello C. In situ polymerase chain reaction detection of transfusion-transmitted virus in liver biopsy. J Viral Hepat. 2002 Mar;9(2):123-7.
- Foschini MP, **Morandi L**, Macchia S, DalMonte PR, Pession A. TT virus-related acute recurrent hepatitis. Histological features of a case and review of the literature. Virchows Arch. 2001 Dec;439(6):752-5. IF:1.709
- Marucci G, **Morandi L**, Macchia S, Betts CM, Tardio ML, Dal Monte PR, Pession A, Foschini MP. Fibrinogen storage disease without hypofibrinogenaemia associated with acute infection. Histopathology. 2003 Jan;42(1):22-5.
- G. Collina, **L. Morandi**, A. Lanzoni, M. Reggiani; Cutaneous atypical mycobacteriosis detected using PCR: report of two cases; Br J Dermatol. 2002 Oct;147(4):781-4.
- Di Tommaso L, Macchia S, **Morandi L**, Leoncini S, Pession A, Dal Monte PR, Foschini MP. Correlation between histologic staging, hepatitis C virus genotypes and clinical features in HCV chronic hepatitis: evidence of a new pattern. Int J Surg Pathol. 2003 Jul;11(3):197-204.
- A. Bordoni, A. Astolfi, F. Danesi, D. de Biase, R. Leghissa, **Morandi L.**, M. di Nunzio, A. Pession (2007). Modulation of gene expression by n-3 PUFAs as a novel adjunctive therapeutic modality for hypertension, cardiac hypertrophy and heart failure. ITALIAN journal of biochemistry, 2007 vol. 56; p. 99, ISSN: 0021-2938
- a. bordoni, a. astolfi, r. leghissa, **morandi l.**, a. pession, f. danesi, m. di nunzio, a. pession (2007). hypertension, cardiac hypertrophy and heart failure: is there a role for n-3 pufas?.

- journal of molecular and cellular cardiology, vol. 42, supplement 1; 2007 p. S143 - S144, ISSN: 0022-2828
- bordoni a, astolfi a, **morandi l.**, pession a, danesi f, di nunzio m, franzoni m, pession a (2007). modulation of cardiac gene expression profile by n-3 pufas and its implication in hypertrophy and heart failure. journal of molecular and cellular cardiology, vol. 42, suppl 1; p. s74, issn: 0022-2828
 - a. bordoni, a. astolfi, **morandi l.**, a. pession, f. danesi, m. di nunzio, p.l. biagi, a. pession (2006). epa and dha incorporate in neonatal rat cardiomyocyte lipids and modulate genes related to cardiac hypertrophy: what is the role of ppar?. chemistry and physics of lipids, 2006, vol. 143; p. 86 - 87, issn: 0009-3084
 - s.damiani, **morandi l.**, s.asioli, a.cavazza, a.pession (2004). iperplasia adenomatosa atipica polmonare. pathologica, 2004, vol. 96; p. 212, issn: 0031-2983
 - **Morandi L**, Pession A, GL Marucci, MP Foschini, G Pruneri, G Viale, V Eusebi; Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma. Hum Pathol. 2003 Dec;34(12):1321-30.
 - **Morandi L**, Asioli S, Cavazza A, Pession A, Damiani S. Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and adenocarcinoma of the lung. Lung Cancer. 2007 Apr;56(1):35-42.
 - **Morandi L**, Marucci G, Foschini MP, Cattani MG, Pession A, Riva C, Eusebi V. Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch. 2006 Jul;449(1):14-23. Epub 2006 Apr 13.
 - Pazzaglia L, Benassi MS, Ragazzini P, Gamberi G, Ponticelli F, Chiechi A, Hattinger CM, **Morandi L**, Alberghini M, Zanella L, Picci P, Mercuri M. Molecular alterations of monophasic synovial sarcoma: loss of chromosome 3p does not alter RASSF1 and MLH1 transcriptional activity. Histol Histopathol. 2006 Feb;21(2):187-95.
 - **Morandi L**, Marucci GL, Eusebi V. DNA mitocondriale e CGH array in patologia mammaria. Pathologica. 2005 Aug;97(4):188-9.
 - **Morandi L** et Al. Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR. J Virol Methods. 2007 Mar;140(1-2):148-54
 - Bordoni A., Astolfi A, **Morandi L.** et Al. N- 3 PUFAs modulate global gene expression profile in cultured rat cardiomyocytes. Implications in cardiac hypertrophy and heart failure. FEBS Lett. 2007 Mar 6;581(5):923-9. Epub 2007 Feb 6.
 - Marucci G, **Morandi L**, Bartolomei I, Salvi F, Pession A, Righi A, Lauria G, Foschini MP. Amyotrophic lateral sclerosis with mutation of the Cu/Zn superoxide dismutase gene (SOD1) in a patient with Down syndrome. Neuromuscul Disord. 2007 Oct;17(9-10):673-6. Epub 2007 Jul 10.
 - Frau DV, Lai ML, Caria P, Dettori T, Coni P, Faa G, **Morandi L**, Tallini G, Vanni R. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. J Clin Endocrinol Metab. 2008 Jan;93(1):177-81. Epub 2007 Oct 23.
 - Foschini MP, Cocchi R, **Morandi L**, Marucci G, Pennesi MG, Righi A, Tosi AL, de Biase D, Pession A, Montebugnoli L. E-cadherin loss and DeltaNp73L expression in oral squamous cell carcinomas showing aggressive behavior. Head Neck. 2008 Nov;30(11):1475-82.
 - Pazzaglia L, Chiechi A, Conti A, Gamberi G, Magagnoli G, Novello C, **Morandi L**, Picci P, Mercuri M, Benassi MS. Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes. Histol Histopathol. 2009 Jan;24(1):61-7.
 - Collina G, **Morandi L**, Bianchi T. HPV16 Identification in Pigmented Lesions of Genital Skin. Pathologica 2008; 100: 206
 - Marucci G, **Morandi L**, Magrini E, Farnedi A, Franceschi E, Miglio R, Calò D, Pession A, Foschini MP, Eusebi V. Gene expression profiling in glioblastoma and immunohistochemical

- evaluation of IGFBP-2 and CDC20. *Virchows Arch.* 2008 Dec;453(6):599-609. Epub 2008 Oct 25.
- de Biase D, **Morandi L**, Tallini G . NCOA4 (Nuclear Receptor Coactivator 4). *Atlas Genet Cytogenet Oncol Haematol.* October 2008 URL : <http://AtlasGeneticsOncology.org/Genes/NCOA4ID218ch10q11.html>
 - de Biase D, **Morandi L**, Tallini G . PAX8 (paired box 8). *Atlas Genet Cytogenet Oncol Haematol.* May 2009 URL : <http://AtlasGeneticsOncology.org/Genes/>
 - Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P, **Morandi L**, Spagnoli F, Ermani M. Recurrence Pattern After Temozolomide Concomitant With And Adjuvant To Radiotherapy In Newly Diagnosed Glioblastoma Patients: Correlation With Mgmt Promoter Methylation *J Clin Oncol.* 2009 Mar 10;27(8):1275-9 IF: 24
 - Righi A, Lenzi S, **Morandi L** et Al. Adenoid cystic carcinoma of the breast associated with invasive duct carcinoma: a case report.. *Int J Surg Pathol.* 2009 Feb 19
 - **Morandi L**, Franceschi E, de Biase D, Marucci GL, Tosoni A, Ermani M, Pession A, Tallini G, Brandes A. Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (*SNURF*) as a reference. *BMC Cancer.* 2010 Feb 18;10:48. IF: 3.32
 - Alba Brandes; Enrico Franceschi; Alicia Tosoni; Stefania Bartolini; Antonella Bacci; Raffaele Agati; Valeria Mazzocchi; Sergio Turazzi; Andrea Talacchi; Milan Skrap; Renato J Galzio; Lorenzo Volpin; **Luca Morandi**; Gianluca Marucci; Alvaro Andreoli; Fabio Calbucci; Mario Ermani MGMT methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. *Neuro Oncol.* 2010 Mar;12(3):283-8. IF: 5.286
 - Agostini M, Enzo MV, **Morandi L**, Bedin C, Pizzini S, Mason S, Bertorelle R, Urso E, Mescoli C, Lise M, Pucciarelli S, Nitti D. A ten markers panel provides a more accurate and complete microsatellite instability analysis in mismatch repair-deficient colorectal tumors. *Cancer Biomark.* 2010 Jan 1;6(1):49-61. IF: 1.186
 - Foschini MP, **Morandi L**, Marchetti C, Cocchi R, Eusebi LH, Farnedi A, Badiali G, Gissi DB, Pennesi MG, Montebugnoli L. Cancerization of cutaneous flap reconstruction for oral squamous cell carcinoma: report of three cases studied with the mtDNA D-loop sequence analysis. *Histopathology.* 2011 Jan 24 IF: 3.301
 - de Biase D, **Morandi L**, Degli Esposti R, Ligorio C, Pession A, Foschini MP, Eusebi V. p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions. *Virchows Arch.* 2010 Apr;456(4):395-401. IF: 2.56
 - Ambrosini-Spaltro A, **Morandi L**, Spagnolo DV, Cavazza A, Brisigotti M, Damiani S, Jain S, Eusebi V. Nasal seromucinous hamartoma (microglandular adenosis of the nose): a morphological and molecular study of five cases. *Virchows Arch.* 2010 Dec;457(6):727-34 IF: 2.560
 - Gamberi G, Cocchi S, Benini S, Magagnoli G, **Morandi L**, Kreshak J, Gambarotti M, Picci P, Zanella L, Alberghini M. Molecular diagnosis in ewing family tumors the rizzoli experience- 222 consecutive cases in four years. *J Mol Diagn.* 2011 May;13(3):313-24. IF: 3.955
 - Marucci G, **Morandi L**. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. *J Neurooncol.* 2011 May 31 IF: 2.787
 - Visani M, de Biase D, Bartolomei I, Plasmati R, **Morandi L**, Cenacchi G, Salvi F, Pession A. A novel T137A SOD1 mutation in an Italian family with two subjects affected by amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* 2011 May 16. IF: 3.091
 - Asioli S, Righi A, de Biase D, **Morandi L**, Caliendo V, Picciotto F, Macripò G, Maletta F, di Cantogno LV, Chiusa L, Eusebi V, Bussolati G. Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) Merkel cell carcinomas. *Mod Pathol.* 2011 Jul 15. doi: 10.1038/modpathol.2011.100 IF: 6.364

- **Morandi L** et Al. T[20] Repeat in the 3'-Untranslated Region of the MT1X Gene: A Marker with High Sensitivity and Specificity to Detect Microsatellite Instability in Colorectal Cancer. *Int J Colorectal Dis.* 2012 May;27(5):647-56 IF: 2.415
- **Morandi L**, De Biase D, Visani M, De Maglio G, Pizzolitto S, Pession A, Tallini G. Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): An accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation. *PLoS One.* 2012;7(4):e36084 IF: 3.534
- de Biase D, Visani M, **Morandi L**, Marucci G, Taccioli C, Cerasoli S, Baruzzi A, Pession A; PERNO Study Group. miRNAs expression analysis in paired fresh/frozen and dissected formalin fixed and paraffin embedded glioblastoma using real-time PCR. *PLoS One.* 2012;7(4):e35596 IF: 3.534
- Tarsitano A, Leonardi E, **Morandi L**, Farnedi A, Montebugnoli L, Marchetti C. Late skip lymph node metastasis of oral squamous cell carcinoma or metastasis of unknown second primary tumor? Answer by mitochondrial DNA analysis. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2012 Jul 19 IF: 1.265
- Pasini E, De Biase D, Visani M, **Morandi L**. Activity of the novel T137A SOD1 mutation in ALS patients *Future Neurol.* (2012) 7(4), 499–503 IF:
- Caria P, Dettori T, Frau DV, Di Oto E, **Morandi L**, Parmeggiani A, Tallini G, Vanni R. Simultaneous Occurrence of PAX8-PPAR γ and RET-PTC3 Rearrangements in a Follicular Variant of Papillary Thyroid Carcinoma. *Am J Surg Pathol.* 2012 Sep;36(9):1415-20. IF: 4.592
- Kurelac I, Mackay A, Lambros MB, Di Cesare E, Cenacchi G, Ceccarelli C, Morra I, Melcarne A, **Morandi L**, Calabrese FM, Attimonelli M, Tallini G, Reis-Filho JS, Gasparre G. Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. *Hum Mol Genet.* 2012 Oct 22. IF: 6.677
- Mustacchi G, Sormani MP, Bruzzi P, Gennari A, Zanconati F, Bonifacio D, Monzoni A, **Morandi L**. Identification and validation of a new set of five genes for prediction of risk in early breast cancer. *Int J Mol Sci.* 2013 May 6;14(5):9686-702 IF: 2.339
- Montebugnoli L, Leonardi E, **Morandi L**, Farnedi A, Gissi DB, Marchetti C, Tarsitano A, Balbi T, Gentile L, Cocchi R, Foschini MP. Genetic relationship between multiple squamous cell carcinomas arising in the oral cavity. *Head Neck.* 2013 Apr 30. doi: 10.1002/hed.23259 IF: 3.006
- Visani M, de Biase D, Marucci G, Taccioli C, Baruzzi A, Pession A; PERNO Study Group. Definition of miRNAs expression profile in glioblastoma samples: the relevance of non-neoplastic brain reference. *PLoS One.* 2013;8(1):e55314. doi: 10.1371/journal.pone.0055314. Epub 2013 Jan 29. IF: 3.534
- Foschini MP, **Morandi L**, Leonardi E, Flamminio F, Ishikawa Y, Masetti R, Eusebi V. Genetic clonal mapping of in situ and invasive ductal carcinoma indicates the field cancerization phenomenon in the breast. *Hum Pathol.* 2013 Jul;44(7):1310-9. doi: 10.1016/j.humpath.2012.09.022. Epub 2013 Jan 18. IF: 2.806
- Righi A, **Morandi L**, Leonardi E, Farnedi A, Marucci G, Sisto A, Frank G, Faustini-Fustini M, Zoli M, Mazzatenta D, Agati R, Foschini MP. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. *Hum Pathol.* 2013 Sep 2. doi:pii: S0046-8177(13)00237-2. 10.1016/j.humpath.2013.05.020 IF: 2.806
- Marucci G, Maresca A, Caporali L, Farnedi A, Betts CM, **Morandi L**, de Biase D, Cerasoli S, Foschini MP, Bonora E, Vidone M, Romeo G, Perli E, Giordano C, d'Amati G, Gasparre G, Baruzzi A, Carelli V, Eusebi V. Oncocytic glioblastoma: a glioblastoma showing oncocytic changes and increased mitochondrial DNA copy number. *Hum Pathol.* 2013 Sep;44(9):1867-76. doi: 10.1016/j.humpath.2013.02.014 IF: 2.806

- Franceschi E, Ermani M, Bartolini S, Bartolotti M, Poggi R, Tallini G, Marucci G, Fioravanti A, Tosoni A, Agati R, Bacci A, Pozzati E, **Morandi L**, Balestrini D, Ghimenton C, Crisi G, Brandes AA. Post progression survival in glioblastoma: where are we? *J Neurooncol*. 2014 Nov 1. IF: 2.787
- Marucci G, **Morandi L**, Mazzatenta D, Frank G, Pasquini E, Foschini MP. MGMT promoter methylation status in clival chordoma. *J Neurooncol*. 2014 Jun;118(2):271-6. doi: 10.1007/s11060-014-1445-y IF: 2.787
- Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Bacchi Reggiani ML, Albani F, Baruzzi A, Pession A; PERNO study group Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. *Mol Oncol*. 2014 Mar;8(2):417-30. doi: 10.1016/j.molonc.2013.12.010. IF: 5.935
- Michelucci R, Pasini E, Meletti S, Fallica E, Rizzi R, Florindo I, Chiari A, Monetti C, Cremonini AM, Forlivesi S, Albani F, Baruzzi A; PERNO Study Group. Epilepsy in primary cerebral tumors: the characteristics of epilepsy at the onset (results from the PERNO study--Project of Emilia Romagna Region on Neuro-Oncology). *Epilepsia*. 2013 Oct;54 Suppl 7:86-91. doi: 10.1111/epi.12314. Review. IF: 4.594
- **Morandi L**, Tarsitano A, Gissi D, Leonardi E, Balbi T, Marchetti C, Montebugnoli L, Foschini MP Clonality analysis in primary oral squamous cell carcinoma and related lymph-node metastasis revealed by TP53 and mitochondrial DNA next generation sequencing analysis. *J Craniomaxillofac Surg*. 2014 Nov 18. pii: S1010-5182(14)00313-8. doi: 10.1016/j.jcms.2014.11.007 IF: 2.597
- Montebugnoli, L., Gissi, D.B., Scapoli, L., Palmieri, A., **Morandi, L.**, Manelli, I., Foschini, M.P. P16INK4 Expression is not associated with human papillomavirus in oral lichen planus *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2014 Dec;118(6):694-702. doi: 10.1016/j.oooo.2014.09.004. IF: 1.46
- Brandes AA, Franceschi E, Ermani M, Tosoni A, Albani F, Depenni R, Faedi M, Pisanello A, Crisi G, Urbini B, Dazzi C, Cavanna L, Mucciarini C, Pasini G, Bartolini S, Marucci G, **Morandi L**, et al. Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center? *Neurooncol Pract*. 2014 Dec;1(4):166-171. Epub 2014 Aug 28
- Franceschi E, Bartolotti M, Tosoni A, Bartolini S, Sturiale C, Fioravanti A, Pozzati E, Galzio R, Talacchi A, Volpin L, **Morandi L**, Danieli D, Ermani M, Brandes AA. The effect of re-operation on survival in patients with recurrent glioblastoma. *Anticancer Res*. 2015 Mar;35(3):1743-8. IF: 1.872
- **Morandi L**, Gissi D, Tarsitano A, Asioli S, Monti V, Del Corso G, Marchetti C, Montebugnoli L, Foschini MP DNA methylation analysis by bisulfite next-generation sequencing for early detection of oral squamous cell carcinoma and high-grade squamous intraepithelial lesion from oral brushing. *J Craniomaxillofac Surg*. 2015 Oct;43(8):1494-500 IF: 2.597
- Marucci G, Fabbri PV, **Morandi L**, De Biase D, Di Oto E, Tallini G, Sturiale C, Franceschi E, Frezza GP, Foschini MP. Pathological spectrum in recurrences of glioblastoma multiforme. *Pathologica*. 2015 Mar;107(1):1-8.
- Gissi DB, Gabusi A, Tarsitano A, Badiali G, Marchetti C, Morandi L, Foschini MP, Montebugnoli L; Ki67 Overexpression in mucosa distant from oral carcinoma: A poor prognostic factor in patients with long-term follow-up. *J Craniomaxillofac Surg*. 2016 Sep;44(9):1430-5
- Righi A, Faustini-Fustini M, **Morandi L** et al. The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3. *Endocrine*. 2016 Aug 4. IF: 3.279

- Asioli S, **Morandi L**, Cavatorta C, Cucchi MC, Foschini MP. The impact of field cancerization on the extent of duct carcinoma in situ (DCIS) in breast tissue after conservative excision. *Eur J Surg Oncol*. 2016 Dec;42(12):1806-1813. doi: 10.1016/j.ejso.2016.07.005. IF: 2.940
- Tarsitano A, Asioli S, **Morandi L**, Monti V, Righi A, Morselli Labate AM, Nardi E, Foschini MP, Marchetti C. Laminin-5 and insulin-like growth factor-II mRNA binding protein-3 (IMP3) expression in preoperative biopsies of oral cancer patients: their role in neural spread risk and survival stratification *J Craniomaxillofac Surg*. 2016 Dec;44(12):1896-1902. doi: 10.1016/j.jcms.2016.07.012 IF: 2.597
- Maria P. Foschini, **Luca Morandi**, Sofia Asioli, Gianluca Giove, Angelo G. Corradini, Vincenzo Eusebi. The morphological spectrum of salivary gland type tumours of the breast.. *Pathology*. 2016 Dec 30. pii: S0031-3025(16)40343-0. doi: 10.1016/j.pathol.2016.10.011 IF: 2.968
- **Luca Morandi**, Alberto Righi, Francesca Maletta, Paola Rucci, Fabio Pagni, Marco Gallo, Sabrina Rossi, Leonardo Caporali, Anna Sapino, Ricardo V. Lloyd, Sofia Asioli. Somatic mutation profiling of Hobnail Variant of Papillary Thyroid Carcinoma. *Endocr Relat Cancer*. 2017 Feb;24(2):107-117. doi: 10.1530/ERC-16-0546 IF: 4.472
- **Morandi L**, Gissi D, Tarsitano A, Asioli S, Gabusi A, Marchetti C, Montebugnoli L, Foschini MP. CpG location and methylation level are crucial factors for the early detection of oral squamous cell carcinoma in brushing samples using bisulfite sequencing of a 13-gene panel. *Clin Epigenetics*. 2017 Aug 15;9:85. doi: 10.1186/s13148-017-0386-7. IF: 4.987
- Gabusi A, **Morandi L**, Asioli S, Foschini MP. Oral field cancerization: history and future perspectives. *Pathologica*. 2017 Mar;109(1):60-65. IF: 0
- Gissi DB, Tarsitano A, Leonardi E, Gabusi A, Neri F, Marchetti C, Montebugnoli L, Foschini MP, **Morandi L**. Clonal analysis as a prognostic factor in multiple oral squamous cell carcinoma. *Oral Oncol*. 2017 Apr;67:131-137. doi: 10.1016/j.oraloncology.2017.02.017 IF: 4.794
- Gissi DB, **Morandi L**, Gabusi A, Tarsitano A, Marchetti C, Cura F, Palmieri A, Montebugnoli L, Asioli S, Foschini MP, Scapoli L. A Noninvasive Test for MicroRNA Expression in Oral Squamous Cell Carcinoma. *Int J Mol Sci*. 2018 Jun 16;19(6). pii: E1789. doi: 10.3390/ijms19061789.
- Di Oto E, Biserni GB, Varga Z, **Morandi L**, Cucchi MC, Masetti R, Foschini MP. X chromosome gain is related to increased androgen receptor expression in male breast cancer. *Virchows Arch*. 2018 May 25. doi: 10.1007/s00428-018-2377-2.
- Gissi DB, Gabusi A, Tarsitano A, Luccarini L, **Morandi L**, Montebugnoli L. Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia. *J Craniomaxillofac Surg*. 2018 May;46(5):759-764. doi: 10.1016/j.jcms.2018.02.016.
- Gamberi G, **Morandi L**, Benini S, Resca A, Cocchi S, Magagnoli G, Donati DM, Righi A, Gambarotti M. Detection of H3F3A p.G35W and p.G35R in giant cell tumor of bone by Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR). *Pathol Res Pract*. 2018 Jan;214(1):89-94. doi: 10.1016/j.prp.2017.10.023.
- Gabusi A, Gissi DB, Tarsitano A, Asioli S, Marchetti C, Montebugnoli L, Foschini MP, **Morandi L**. Intratumoral Heterogeneity in Recurrent Metastatic Squamous Cell Carcinoma of the Oral Cavity: New Perspectives Afforded by Multiregion DNA Sequencing and mtDNA Analysis. *J Oral Maxillofac Surg*. 2019 Feb;77(2):440-455. doi: 10.1016/j.joms.2018.09.014
- Ricci C, **Morandi L**, Righi A, Gibertoni D, Maletta F, Ambrosi F, Agostinelli C, Uccella S, Asioli S, Sessa F, Pellilli M, Maragliano R, La Rosa S, Papotti MG, Asioli S. PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. *Mod Pathol*. 2019 Apr 11. doi: 10.1038/s41379-019-0261-5. IF: 6.655

- Renzi A, De Bonis P, **Morandi L**, Lenzi J, Tinto D, Rigillo A, Bettini G, Bellei E, Sabattini S. Prevalence of p53 dysregulations in feline oral squamous cell carcinoma and non-neoplastic oral mucosa. *PLoS One*. 2019 Apr 18;14(4):e0215621. doi: 10.1371/journal.pone.0215621. eCollection 2019 IF:2.766
- Gabusi A, Gissi DB, Montebugnoli L, Asioli S, Tarsitano A, Marchetti C, Balbi T, Helliwell TR, Foschini MP, **Morandi L**. Prognostic impact of intra-field heterogeneity in oral squamous cell carcinoma. *Virchows Arch*. 2019 Aug 29. doi: 10.1007/s00428-019-02656-z IF: 2.848
- Maresca A, Del Dotto V, Capristo M, Scimonelli E, Tagliavini F, **Morandi L**, Tropeano CV, Caporali L, Mohamed S, Roberti M, Scandiffio L, Zaffagnini M, Rossi J, Cappelletti M, Musiani F, Contin M, Riva R, Liguori R, Pizza F, La Morgia C, Antelmi E, Polosa PL, Mignot E, Zanna C, Plazzi G, Carelli V. DNMT1 mutations leading to neurodegeneration paradoxically reflect on mitochondrial metabolism. *Hum Mol Genet*. 2020 Jan 27. pii: ddaa014. doi: 10.1093/hmg/ddaa014 IF: 4.544
- Gissi DB, Tarsitano A, Gabusi A, Rossi R, Attardo G, Lenzi J, Marchetti C, Montebugnoli L, Foschini MP, **Morandi L**. 13-gene DNA Methylation Analysis from Oral Brushing: A Promising Non Invasive Tool in the Follow-up of Oral Cancer Patients. *J Clin Med*. 2019 Dec 2;8(12). pii: E2107. doi: 10.3390/jcm8122107. IF: 5.583
- Asioli S, Zoli M, Guaraldi F, Sollini G, Bacci A, Gibertoni D, Ricci C, **Morandi L**, Pasquini E, Righi A, Mazzatenta D. Peculiar pathological, radiological and clinical features of skull base dedifferentiated chordomas. Results from a referral Center case series and literature review. *Histopathology*. 2019 Oct 25. doi: 10.1111/his.14024 IF: 3.294
- Corradini A, Asioli S, **Morandi L**, Brotto M, Righi A, Iommi M, Rucci P, Asioli S, Sapino A, Viale G, Foschini MP. Post-radiotherapy vascular lesions of the breast: immunohistochemical and molecular features of 74 cases with long term follow up and literature review. *Histopathology* 2020 Aug;77(2):293-302. IF: 3.294
- Gissi DB, Gabusi A, Tarsitano A, Rossi R, Balbi T, **Morandi L**. Multi-Region Sequence Analysis of a Pregnancy-Related Oral Squamous Cell Carcinoma Exhibiting Low-Level Aggressive Behavior. *Int J Surg Pathol*. 2019 Sep 22:1066896919876058. doi: 10.1177/1066896919876058 IF:0.975
- Gissi DB, Fabbri VP, Gabusi A, Lenzi J, **Morandi L**, Melotti S, Asioli S, Tarsitano A, Balbi T, Marchetti C, Montebugnoli L. Pre-Operative Evaluation of DNA Methylation Profile in Oral Squamous Cell Carcinoma Can Predict Tumor Aggressive Potential. *Int J Mol Sci*. 2020 Sep 14;21(18):E6691. doi: 10.3390/ijms21186691. IF: 4.556
- **Morandi L**, Sabattini S, Renzi A, Rigillo A, Bettini G, Dervas E, Schauer A, Morandi M, Gissi DB, Tarsitano A, Evangelisti S, Tonon C. An Evolutionary Cancer Epigenetic Approach Revealed DNA Hypermethylation of Ultra-Conserved Non-Coding Elements in Squamous Cell Carcinoma of Different Mammalian Species. *Cells*. 2020 Sep 13;9(9):E2092. doi: 10.3390/cells9092092. IF: 4.366
- Di Dalmazi G, **Morandi L**, Rubin B, Pilon C, Asioli S, Vicennati V, De Leo A, Ambrosi F, Santini D, Pagotto U, Maffeis V, Fassina A, Fallo F. DNA Methylation of steroidogenic enzymes in benign adrenocortical tumors: new insights in aldosterone-producing adenomas. *J Clin Endocrinol Metab*. 2020 Aug 26:dga585. doi: 10.1210/clinem/dga585 IF: 5.6
- Dimartino P, Mariani V, Marconi C, Minardi R, Bramerio M, Licchetta L, Menghi V, **Morandi L**, Magini P, Mongelli P, Cardinale F, Seri M, Tinuper P, Tassi L, Pippucci T, Bisulli F. Accurate Detection of Hot-Spot MTOR Somatic Mutations in Archival Surgical Specimens of Focal Cortical Dysplasia by Molecular Inversion Probes. *Mol Diagn Ther*. 2020 Oct;24(5):571-577. doi: 10.1007/s40291-020-00488-1. IF: 3.18
- Foschini MP, **Morandi L**, Sanchez AM, Santoro A, Mulè A, Zannoni GF, Varga Z, Moskovszky L, Cucchi MC, Moelans CB, Giove G, van Diest PJ, Masetti R. Methylation

- Profile of X-Chromosome-Related Genes in Male Breast Cancer. *Front Oncol.* 2020 Jun 17;10:784. doi: 10.3389/fonc.2020.00784 IF: 2.53
- Gissi DB, Gabusi A, Tarsitano A, Asioli S, Rossi R, Marchetti C, Montebugnoli L, Foschini MP, **Morandi L**. Application of a non-invasive oral brushing procedure based on bisulfite sequencing of a 13-gene panel to study high-risk OSCC patients. *Cancer Biomark.* 2020;28(4):499-510. doi: 10.3233/CBM-190422. IF: 3.436
 - Renzi A, **Morandi L**, Lenzi J, Rigillo A, Bettini G, Bellei E, Giacomini A, Tinto D, Sabattini S. Analysis of DNA methylation and TP53 mutational status for differentiating feline oral squamous cell carcinoma from non-neoplastic mucosa: A preliminary study. *Vet Comp Oncol.* 2020 Jun 7. doi: 10.1111/vco.12624 IF: 1.749
 - Guaraldi F, Zoli M, Righi A, Gibertoni D, Marino Picciola V, Faustini-Fustini M, **Morandi L**, Bacci A, Pasquini E, Mazzatenta D, Asioli S. A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s. *Clin Endocrinol (Oxf).* 2020 Jul;93(1):36-43. doi: 10.1111/cen.14197 IF: 3.38
 - Abu-Rumeileh S, Vacchiano V, Zenesini C, Polischi B, de Pasqua S, Fileccia E, Mammana A, Di Stasi V, Capellari S, Salvi F, Liguori R, Parchi P; BoReALS. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. *J Neurol.* 2020 Jun;267(6):1699-1708. doi: 10.1007/s00415-020-09761-z.
 - Rusciano I, Marvi MV, Owusu Obeng E, Mongiorgi S, Ramazzotti G, Follo MY, Zoli M, **Morandi L**, Asioli S, Fabbri VP, McCubrey JA, Suh PG, Manzoli L, Cocco L, Ratti S. Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology *Adv Biol Regul.* 2020 Nov 28;100771. doi: 10.1016/j.jbior.2020.100771
 - Cremonini A, Saragoni L, **Morandi L**, Corradini AG, Ravaioli C, Di Oto E, Limarzi F, Sanchez AM, Cucchi MC, Masetti R, Quinn C, Foschini MP. Chromosome X aneusomy and Androgen Receptor gene copy number aberrations in apocrine carcinoma of the breast. *Virchows Arch.* 2021 Aug;479(2):345-354. doi: 10.1007/s00428-021-03028-2. IF: 2.848
 - Ricci C, **Morandi L**, Ambrosi F, Righi A, Gibertoni D, Maletta F, Agostinelli C, Corradini AG, Uccella S, Asioli S, Sessa F, La Rosa S, Papotti MG, Asioli S. Intron 4-5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinicopathological Features and Prognostic Relevance. *Endocr Pathol.* 2021 Sep;32(3):385-395. doi: 10.1007/s12022-021-09669-y. IF:3.943
 - Renzi A, **Morandi L**, Bellei E, Marconato L, Rigillo A, Aralla M, Lenzi J, Bettini G, Tinto D, Sabattini S. Validation of oral brushing as a non-invasive technique for the identification of feline oral squamous cell carcinoma by DNA methylation and TP53 mutation analysis. *Vet Comp Oncol.* 2021 Sep;19(3):501-509. doi: 10.1111/vco.12688 IF:2.613
 - Gissi DB, **Morandi L**, Colella G, De Luca R, Campisi G, Mauceri R, Romeo U, Tenore G, Mignogna MD, Adamo D, Oteri G, Marcianò A, Vescovi P, Meleti M, Serpico R, Di Stasio D, Pentenero M, Santarelli A, Bianchi A, Crimi S, Marchetti C, Tarsitano A, Foschini MP, Montebugnoli L. Clinical validation of 13-gene DNA methylation analysis in oral brushing samples for detection of oral carcinoma: Italian multicenter study. *Head Neck.* 2021 May;43(5):1563-1573. doi: 10.1002/hed.26624. IF: 2.310
 - Tresch NS, Fuchs D, **Morandi L**, Tonon C, Rohrer Bley C, Nytko KJ. Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines *Vet Med Sci.* 2021 Nov;7(6):2124-2134.
 - Ratti S, Marvi MV, Mongiorgi S, Obeng EO, Rusciano I, Ramazzotti G, **Morandi L**, Asioli S, Zoli M, Mazzatenta D, Suh PG, Manzoli L, Cocco L. Impact of phospholipase C β 1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness *Cell Mol Life Sci* 2022 Mar 18;79(4):195

- Rossi R, Gissi DB, Gabusi A, Fabbri VP, Balbi T, Tarsitano A, **Morandi L.** A 13-Gene DNA Methylation Analysis Using Oral Brushing Specimens as an Indicator of Oral Cancer Risk: A Descriptive Case Report. *Diagnostics (Basel)*. 2022 Jan 23;12(2):284.
- Marvi MV, Mongiorgi S, Ramazzotti G, Follo MY, Billi AM, Zoli M, Mazzatenta D, **Morandi L**, Asioli S, Papa V, McCubrey JA, Suh PG, Manzoli L, Cocco L, Ratti S. Role of PLC γ 1 in the modulation of cell migration and cell invasion in glioblastoma *Adv Biol Regul*. 2022 Jan;83:100838.
- Farolfi A, Altavilla A, Morandi L, Capelli L, Chiadini E, Prisinzano G, Gurioli G, Molari M, Calistri D, Foschini MP, De Giorgi U. Endometrioid Cancer Associated With Endometriosis: From the Seed and Soil Theory to Clinical Practice *Front Oncol*. 2022 Mar 10;12:859510.
- Ravaioli F, Zampieri M, Morandi L, Pirazzini C, Pellegrini C, De Fanti S, Gensous N, Pirazzoli GL, Sambati L, Ghezzi A, Ciccarone F, Reale A, Monti D, Salvioli S, Caiafa P, Capri M, Bürkle A, Moreno-Villanueva M, Garagnani P, Franceschi C, Bacalini MG. DNA Methylation Analysis of Ribosomal DNA in Adults With Down Syndrome. *Front Genet*. 2022 Apr 27;13:792165
- Micaela Mitolo, Matteo Zoli, Claudia Testa, Luca Morandi, Magali Jane Rochat, Fulvio Zaccagna, Matteo Martinoni, Francesca Santoro, Sofia Asioli, Filippo Badaloni, Alfredo Conti, Carmelo Sturiale, Raffaele Lodi, Diego Mazzatenta, Caterina Tonon. Neuroplasticity mechanisms in frontal brain gliomas. *Front Neurol*. 2022 Jun 3;13:867048.
- Barone V, La Morgia C, Caporali L, Fiorini C, Carbonelli M, Gramegna LL, Bartiromo F, Tonon C, Morandi L, Liguori R, Petrini A, Brugnano R, Del Sordo R, Covarelli C, Morrioni M, Lodi R, Carelli V. Case Report: Optic Atrophy and Nephropathy With m.13513G>A/MT-ND5 mtDNA Pathogenic Variant; *Front Genet* . 2022 Jun 3;13:887696
- Gabusi A, Gissi DB, Grillini S, Stefanini M, Tarsitano A, Marchetti C, Foschini MP, Montebugnoli L, Morandi L. Shared epigenetic alterations between oral cancer and periodontitis: A preliminary study; *Oral Dis*. 2022 May 14
- Stefania Evangelisti, Laura Ludovica Gramegna, Silvia De Pasqua, Magali Jane Rochat, Luca Morandi, Micaela Mitolo, Claudio Bianchini, Gianfranco Vornetti, Claudia Testa, Patrizia Avoni, Rocco Liguori, Raffaele Lodi, Caterina Tonon. In vivo parieto-occipital white matter metabolism is correlated with visuospatial deficits in adult DM1 patients. Accepted for publication in *Diagnostics* Manuscript ID: diagnostics-1871407
- Federica Guaraldi, Luca Morandi, Matteo Zoli, Diego Mazzatenta, Alberto Righi, Stefania Evangelisti, Francesca Ambrosi, Caterina Tonon, Caterina Giannini, Ricardo V. Lloyd, Sofia Asioli. Epigenomic and Somatic Mutations of Pituitary Tumors with clinical and pathological correlations in 111 patients. Accepted for publication in *Clinical Endocrinology* CEN-2022-000464.R1

In compliance with the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned decree.

Dr Luca Morandi

